Erratum: Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice
- PMID: 27389496
- PMCID: PMC4936511
- DOI: 10.1038/srep28124
Erratum: Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice
Erratum for
-
Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice.Sci Rep. 2016 May 26;6:26428. doi: 10.1038/srep26428. Sci Rep. 2016. PMID: 27226136 Free PMC article.
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous